Description
Vocabria (cabotegravir) is a medication used in the treatment and prevention of HIV-1 infection. It is a type of antiretroviral therapy that is taken in combination with another HIV medication. Cabotegravir belongs to a class of drugs called integrase strand transfer inhibitors, which stop the virus from multiplying, reducing the amount of HIV in the body.
Uses:
Vocabria is used for the treatment of HIV-1 infection in adults who have not previously received treatment for the virus. It is also used for the prevention of HIV-1 infection in adults at risk of acquiring HIV-1 through sexual activity.
Storage Conditions:
Vocabria should be stored at room temperature, between 68°F and 77°F (20°C and 25°C). It should be kept in its original packaging until ready to use.
Mechanism of Action:
Cabotegravir works by blocking an enzyme called integrase that is involved in the replication of the HIV virus. By inhibiting this enzyme, Vocabria prevents the virus from inserting its genetic material into the DNA of human cells, effectively stopping the virus from replicating.
How to Use:
Vocabria is administered as an injection into the muscle (intramuscular injection) by a healthcare provider. The recommended dosage for treatment is 600mg injected once every four weeks, while the recommended dosage for prevention is 600mg injected once every eight weeks. Careful monitoring for an hour after injection is required to ensure that there are no immediate allergic reactions.
Precautions:
Before taking Vocabria, it is important to inform your healthcare provider of any allergies, medical conditions, and medications you are currently taking. Vocabria may cause adverse reactions, such as liver and kidney problems, allergic reactions, and a decrease in bone mineral density. Patients with liver or kidney problems may require dosage adjustments or additional monitoring during treatment. Pregnant and breastfeeding women should discuss the risks and benefits of using Vocabria with their healthcare provider.
Drug Interactions:
Vocabria may interact with other medications, including antacids, rifampin, and certain antiseizure medications. Patients should inform their healthcare provider of any medications they are taking before beginning treatment with Vocabria.
Contraindications:
Vocabria is contraindicated in patients who have previously experienced an allergic reaction to the medication. It should not be used in patients with severe liver or kidney problems.
Overdose:
There is limited information on overdoses of Vocabria, but symptoms may include nausea, vomiting, and stomach pain. If an overdose is suspected, medical attention should be sought immediately.
Adverse Reactions:
The most common adverse reactions reported with Vocabria include injection site reactions, nausea, and headaches. Other adverse reactions may include liver and kidney problems, anemia, and depression. Patients should report any adverse reactions to their healthcare provider immediately.
Reviews
There are no reviews yet.